close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ovid Therapeutics Inc. - Common Stock (NQ:OVID)

1.424 -0.036 (-2.48%)
Streaming Delayed Price Updated: 9:52 AM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ovid Therapeutics Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued... 
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costs 
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights 
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Host Investor Event
KCC2 Download Day on Wednesday, November 13, 2024 
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present at Upcoming September Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Ovid Therapeutics to Present at Upcoming August Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the Brain 
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today